MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1245/s10434-025-19050-6

Медицинская библиотека · Annals of surgical oncology · 2026

Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.

Kita Ryosuke, Kato Ken, Machida Ryunosuke, Ito Yoshinori, Daiko Hiroyuki, Kawakubo Hirofumi, Sasaki Keita, Fukuda Haruhiko, Kimura Yasue, Akiyoshi Kohei, Koyanagi Kazuo, Hara Hiroki, Minashi Keiko, Amagai Kenji, Abe Tetsuya, Matsuda Satoru, Tsushima Takahiro, Takeuchi Hiroya

СтатьяКлиническое исследование III фазыРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The optimal timing of surgery following neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) remains uncertain. This exploratory analysis aims to assess the impact of time to surgery (TTS) on perioperative and survival outcomes in patients with advanced ESCC enrolled in the phase III trial JCOG1109.

METHODS

Patients who underwent esophagectomy following neoadjuvant chemotherapy or chemoradiotherapy were included. Within each treatment arm, patients were categorized into four TTS subgroups according to cohort quartiles. Perioperative complications, overall survival (OS), and progression-free survival (PFS) were evaluated.

RESULTS

The median TTS was 35 (range, 16-81), 38 (17-109), and 41 (14-98) days for the cisplatin plus fluorouracil (CF), docetaxel, cisplatin plus fluorouracil, and CF with radiotherapy (CF-RT) arms, respectively. Baseline characteristics were comparable across the TTS subgroups. Operative time and overall complication rates showed no significant differences. In the CF-RT arm, a longer TTS was associated with increased blood loss (200, 210, 300, and 370 mL) and a trend toward a higher anastomotic leakage (6%, 7%, 14%, and 18%), as well as a trend toward poorer PFS and OS, particularly at more prolonged intervals. However, across all treatment arms, OS and PFS did not differ among the TTS subgroups, with multivariable analysis revealing no consistent associations between TTS and survival.

CONCLUSIONS

Time to surgery following neoadjuvant therapy did not significantly influence prognosis in advanced ESCC. Nonetheless, prolonged intervals after chemoradiotherapy may increase surgical complexity and leakage risk, in addition to elevating the potential for adverse prognostic effects associated with excessive delays.

Для цитирования: Kita Ryosuke, Kato Ken, Machida Ryunosuke, Ito Yoshinori, Daiko Hiroyuki, Kawakubo Hirofumi, Sasaki Keita, Fukuda Haruhiko, Kimura Yasue, Akiyoshi Kohei, Koyanagi Kazuo, Hara Hiroki, Minashi Keiko, Amagai Kenji, Abe Tetsuya, Matsuda Satoru, Tsushima Takahiro, Takeuchi Hiroya. Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.. Annals of surgical oncology. 2026. DOI: 10.1245/s10434-025-19050-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.